In Familial Alzheimer’s, β-Synuclein Rises in Blood a Decade Before Onset
In ADAD mutation carriers, blood β-synuclein crept up after their amyloid-PET scans had turned positive, but before axons degenerated. Does it reflect crumbling synapses?
NEWS
What’s Inside Those Mysterious Biondi Bodies? Hello, TMEM106B!
Cryo-EM identifies a similar protein fold in these ependymal cell inclusions as in parenchymal TMEM106b fibrils.
Just as Sharp: MRI Scans at Triple the Speed
By utilizing advances in parallel imaging, scientists cut the time needed for diagnostic MRI scans from 18 to 6.5 minutes, without a noticeable loss in quality.
Beyond Antibodies: From CTAD, New Attempts at Outflanking Alzheimer’s
Early stage trials hint that new therapeutics could take down APP, boost ApoE2, or fix inflammatory and metabolic dysfunction in AD.
Some Alzheimer’s Blood Tests Are Racing Toward IVD Certification
Vendors of plasma p-tau217-based tests are filing with U.S. and European regulators for approval of fully automated, in vitro diagnostics.
Biomarkers Suggest Black and Hispanic People Less Likely to Have Amyloid
The findings suggest that non-AD pathologies, driven by other comorbidities, might contribute to cognitive decline in these populations.
AI to Spot ARIA? FDA Says Yes
The commercial software icobrain aria sharpened radiologists’ detection of ARIA-E and ARIA-H. The FDA approved the technology for clinical use November 7.
Fully Loaded: Secondary Prevention Studies of Lecanemab, Donanemab
In Madrid, researchers touted the benefits of plasma prescreening and showed baseline data on these early AD populations. Meanwhile, remternetug has begun Phase 3.
SPOTLIGHT
From Madrid, News on Underrepresented Groups, Drug Trials, MRI and Blood Tests
This week, more news from CTAD. Alzheimerologists learned that, after years of trying to fold more underrepresented groups into trials, they were indeed reaching and screening more non-white people, but so many of them do not have brain amyloid that their enrollment percentage is still low. On the up side: tools keep improving. MRI is speeding up, AI can help spot ARIA, and p-tau blood tests are heading toward certification as in vitro diagnostics. And while two anti-amyloid antibodies are a nice start, researchers are trialing many more ways to fight AD.
Join The Conversation
Professional Resources
New in last 7 days
-
Grants
- New Items: 9
- Total Items: 282
-
Jobs
- New Items: 1
- Total Items: 31
-
Conference Calendar
- New Items: 1
- Total Items: 89
- Member Directory
Latest Comments